Absci/$ABSI
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Absci
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.
- Ticker
- $ABSI
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 140
- Headquarters
- Vancouver, United States
- Website
- www.absci.com
Absci Metrics
BasicAdvanced
$1.7B
-
-$0.80
2.44
-
Price and volume
Market cap
$1.7B
Beta
2.44
52-week high
$12.54
52-week low
$2.24
Average daily volume
4.2M
Financial strength
Current ratio
10.627
Quick ratio
10.263
Long term debt to equity
0.007
Total debt to equity
0.016
Interest coverage (TTM)
-1,389.36%
Profitability
EBITDA (TTM)
-119.506
Gross margin (TTM)
-5,395.64%
Net profit margin (TTM)
-7,756.37%
Operating margin (TTM)
-8,366.43%
Revenue per employee (TTM)
$10,000
Management effectiveness
Return on assets (TTM)
-34.10%
Return on equity (TTM)
-57.72%
Valuation
Price to revenue (TTM)
939.682
Price to book
6.75
Price to tangible book (TTM)
8.07
Price to free cash flow (TTM)
-13.46
Free cash flow yield (TTM)
-7.43%
Free cash flow per share (TTM)
-0.72
Growth
Revenue change (TTM)
-62.28%
Earnings per share change (TTM)
-15.15%
3-year revenue growth (CAGR)
-43.30%
3-year earnings per share growth (CAGR)
-13.18%
What the Analysts think about Absci
Analyst ratings (Buy, Hold, Sell) for Absci stock.
Analyst projections of the future price of Absci stock.
Bulls say / Bears say
Interim Phase 1 results for ABS-201 showed no serious adverse events and an estimated half-life of at least 65 days. That supports the potential for a convenient two- or three-dose schedule over six months, although the data are still early. (GlobeNewswire)
Eli Lilly invested $40 million in Absci’s $100 million share offering, and cash and marketable securities stood at $201.1 million at June-end. Management expects that balance to fund its plans into the second half of 2028, covering important clinical readouts. (GlobeNewswire)
ABS-201 is being developed for both pattern hair loss and endometriosis. Absci has outlined a randomised, placebo-controlled Phase 2 endometriosis trial with pain endpoints, giving the drug a potential second use if the study proceeds and succeeds. (GlobeNewswire)
ABS-201 has not yet demonstrated hair growth in people. The interim Phase 1 update covered safety and drug levels, while the first proof-of-concept results were still pending, leaving the central efficacy case unproven. (Pharmaceutical Technology)
Partner-programme revenue was only $0.3 million in the second quarter of 2026, while Absci’s net loss widened to $33.2 million. The company therefore remains dependent on future clinical progress rather than a substantial recurring revenue base. (GlobeNewswire)
The endometriosis Phase 2 trial is still some way off: Absci’s latest plan targets a mid-2027 start, subject to review of ongoing safety and drug-level data, protocol finalisation and regulatory clearance. That leaves meaningful timing and execution risk before the programme can produce efficacy evidence. (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 14 Oct 2026.
Absci Financial Performance
Revenues and expenses
Absci Earnings Performance
Company profitability
Upcoming events
No upcoming events
Absci News
AllArticlesVideos
Funds containing Absci
Fund name | Fund size | $ABSI weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.16% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.16% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.16% |
iShares Ageing Population$AGED | $953M | 0.15% |
iShares Ageing Population£AGES | $953M | 0.15% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.